UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus

Clinical therapeutics, 2016-10, Vol.38 (10), p.e1-e1

Milicevic, Z

2016

Volltextzugriff (PDF)

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.849-858

2015

Volltextzugriff (PDF)

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

Diabetic medicine, 2012-10, Vol.29 (10), p.1260-1267

2012

Volltextzugriff (PDF)

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

Diabetes, obesity & metabolism, 2014-08, Vol.16 (8), p.748-756

2014

Volltextzugriff (PDF)

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

Diabetes, obesity & metabolism, 2016-05, Vol.18 (5), p.533-536

2016

Volltextzugriff (PDF)

Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2016-08, Vol.18 (8), p.834-839

2016

Volltextzugriff (PDF)

1.2 - Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus

Clinical therapeutics, 2016-10, Vol.38 (10), p.e1-e1

Milicevic, Z.

2016

Volltextzugriff (PDF)

P314 Évaluation des principaux résultats du dulaglutide en administration hebdomadaire comparé à l’insuline glargine, tous deux associés à l’insuline prandiale lispro, selon le taux initial d’HbA1c chez les patients diabétiques de type 2 (DT2) inclus dans l’esssai AWARD-4 (Assessment of weekly administration of dulaglutide in diabetes 4)

Diabetes & metabolism, 2015-03, Vol.41, p.A113-A113

2015

Volltextzugriff (PDF)

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.849-858

2015

Volltextzugriff (PDF)

А critical role for molecular chaperones in Alzheimer's disease

Journal of the neurological sciences, 2013-10, Vol.333, p.e349-e349

2013

Volltextzugriff (PDF)

Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression

International journal of oncology, 2008-06, Vol.32 (6), p.1169-1178

2008

Volltextzugriff (PDF)

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Lancet (British edition), 2018-11, Vol.392 (10160), p.2180-2193

2018

Volltextzugriff (PDF)

Performance of aquatic weed - Waste Myriophyllum spicatum immobilized in alginate beads for the removal of Pb(II)

Journal of environmental management, 2019-02, Vol.232, p.97-109

2019

Volltextzugriff (PDF)

Mechanism of stearic acid adsorption to calcite

Powder technology, 2013-09, Vol.245, p.208-216

2013

Volltextzugriff (PDF)

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications

Experimental and clinical endocrinology & diabetes, 2009-05, Vol.117 (5), p.223-229

2009

Volltextzugriff (PDF)

THE EFFECT OF TIRZEPATIDE DURING WEIGHT LOSS ON FOOD INTAKE, APPETITE, FOOD PREFERENCE AND FOOD CRAVING IN PEOPLE WITH OBESITY

Canadian journal of cardiology, 2023-10, Vol.39 (10), p.S239-S239

2023

Volltextzugriff (PDF)

A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan

Diabetes research and clinical practice, 2003-02, Vol.59 (2), p.137-143

2003

Volltextzugriff (PDF)

THE EFFECT OF TIRZEPATIDE DURING WEIGHT LOSS ON FOOD INTAKE, APPETITE, FOOD PREFERENCE AND FOOD CRAVING IN PEOPLE WITH OBESITY

Canadian journal of diabetes, 2023-11, Vol.47 (7), p.S199-S199

2023

Volltextzugriff (PDF)

Continuous glucose monitoring in type 2 diabetes patients treated with once weekly dulaglutide or once daily glargine, both combined with insulin lispro (AWARD-4 substudy)

Diabetologia, 2015, Vol.58, p.S38

2015

Volltextzugriff (PDF)

A quantitative morphometric study of rectal mucosa in adult and aged healthy subjects

Histology and histopathology, 2007-04, Vol.22 (4), p.433

2007

Volltextzugriff (PDF)

Cytogenetic effects of 8-Cl-cAMP on human and animal chromosomes

Journal of B.U. ON., 2009-01, Vol.14 (1), p.71

2009

Volltextzugriff (PDF)

Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma--immunohistochemistry and Western blot analysis

Neoplasma, 2007, Vol.54 (1), p.37

2007

Volltextzugriff (PDF)

Interventions in diabetic patients after myocardial infarction

Acta diabetologica, 2003-12, Vol.40 Suppl 2, p.S348-s353

2003

Volltextzugriff (PDF)

Deregulated sequential motion of centromeres induced by antitumor agents may lead to genome instability in human peripheral blood lymphocytes

Journal of B.U. ON., 2007-01, Vol.12 (1), p.77

2007

Volltextzugriff (PDF)

P187 Après un repas mixte hyperlipidique, l’hyperglycémie postprandiale et non l’insulinémie postprandiale entraîne une augmentation des marqueurs inflammatoires et du stress nitro-oxydant chez des patients diabétiques de type 2

Diabetes & metabolism, 2008, Vol.34, p.H92-H92

2008

Volltextzugriff (PDF)

1 – 25 von 316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(208)
Mit Volltextzugriff
(246)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(279)
Croatian
(22)
Serbian
(16)
Deutsch
(4)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(155)
Life Sciences & Biomedicine
(111)
Humans
(97)
Male
(87)
Female
(80)
Middle Aged
(48)
Animals
(44)
Adult
(38)
Technology
(38)
Aged
(35)
Biological And Medical Sciences
(34)
Rats
(33)
Medical Sciences
(25)
Endocrinology & Metabolism
(21)
Computer Science
(20)
Social Sciences
(18)
Thymus Gland - Cytology
(18)
Computer Science, Artificial Intelligence
(16)
Diabetes Mellitus, Type 2 - Drug Therapy
(16)
Public Health
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes

1.2 - Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

А critical role for molecular chaperones in Alzheimer's disease

Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Performance of aquatic weed - Waste Myriophyllum spicatum immobilized in alginate beads for the removal of Pb(II)

Mechanism of stearic acid adsorption to calcite

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications

THE EFFECT OF TIRZEPATIDE DURING WEIGHT LOSS ON FOOD INTAKE, APPETITE, FOOD PREFERENCE AND FOOD CRAVING IN PEOPLE WITH OBESITY

A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan

THE EFFECT OF TIRZEPATIDE DURING WEIGHT LOSS ON FOOD INTAKE, APPETITE, FOOD PREFERENCE AND FOOD CRAVING IN PEOPLE WITH OBESITY

Continuous glucose monitoring in type 2 diabetes patients treated with once weekly dulaglutide or once daily glargine, both combined with insulin lispro (AWARD-4 substudy)

A quantitative morphometric study of rectal mucosa in adult and aged healthy subjects

Cytogenetic effects of 8-Cl-cAMP on human and animal chromosomes

Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma--immunohistochemistry and Western blot analysis

Interventions in diabetic patients after myocardial infarction

Deregulated sequential motion of centromeres induced by antitumor agents may lead to genome instability in human peripheral blood lymphocytes

P187 Après un repas mixte hyperlipidique, l’hyperglycémie postprandiale et non l’insulinémie postprandiale entraîne une augmentation des marqueurs inflammatoires et du stress nitro-oxydant chez des patients diabétiques de type 2

Suchergebnisse filtern